(NASDAQ: IMMP) Immutep's forecast annual revenue growth rate of 150.99% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 108.37%, and it is also forecast to beat the US market's average forecast revenue growth rate of 25.15%.
Immutep's revenue in 2025 is $6,708,683.On average, 6 Wall Street analysts forecast IMMP's revenue for 2026 to be $8,604,615,376, with the lowest IMMP revenue forecast at $5,724,727,134, and the highest IMMP revenue forecast at $13,033,976,957. On average, 5 Wall Street analysts forecast IMMP's revenue for 2027 to be $4,424,980,412, with the lowest IMMP revenue forecast at $0, and the highest IMMP revenue forecast at $7,667,045,269.
In 2028, IMMP is forecast to generate $186,900,657,809 in revenue, with the lowest revenue forecast at $4,722,899,886 and the highest revenue forecast at $641,388,497,444.